Skeleton Pirate

Skeleton Pirate
Artist: LindaB

WELCOME TO STRONTIUM FOR BONES BLOG

Have you experienced, or read about, negative, and even dangerous, side effects from Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate), and other bisphosphonates prescribed for osteoporosis? If you have, then rest assured there is a safe, effective treatment for this condition. Strontium, primarily in the form of strontium citrate, is taken orally once a day.

Visitors to my blog can leave comments or ask questions and can remain anonymous, if they wish. Their comments are relayed to my g-mail inbox. Below each post, the number of comments for that post is cited and underlined because it is a link. By clicking on that link below any post, a window opens so that a visitor can leave a comment. Ideally, visitors leave comments on posts most relevant to their comments. All comments to my posts are moderated by me.

Browse the posts and visit the link library of references.

Visit me at www.twitter.com






Blog Archive

Monday, July 7, 2014

Prevalence and Determinants of Osteoporosis in Patients With Type 1 and Type 2 Diabetes Mellitus



We analyze osteoporosis prevalence and determinants of bone mineral density (BMD) in patients with type 1 and 2 diabetes.  Three hundred and ninety-eight consecutive diabetic patients from a single outpatient clinic received a standardized questionnaire on osteoporosis risk factors and were evaluated for diabetes-related complications, HbA1c levels, and lumbar spine (LS) and femoral neck (FN) BMD. Of these, 139 (71 men, 68 women) type 1 and 243 (115 men, 128 women) type 2 diabetes patients were included in the study. BMD (T-scores and values adjusted for age, BMI and duration of disease) was compared between patient groups and between patients with type 2 diabetes and population-based controls (255 men, 249 women).

For both genders, adjusted BMD was not different between the type 1 and type 2 diabetes groups but was higher in the type 2 group compared with controls. Osteoporosis prevalence (BMD T-score < −2.5 SD) at FN and LS was equivalent in the type 1 and type 2 diabetes groups, but lower in type 2 patients compared with controls (FN: 13.0% vs 21.2%, LS: 6.1% vs 14.9% men; FN: 21.9% vs 32.1%, LS: 9.4% vs 26.9% women). Osteoporosis prevalence was higher at FN-BMD than at LS-BMD. BMD was positively correlated with BMI and negatively correlated with age, but not correlated with diabetes-specific parameters (therapy, HbBA1c, micro- and macrovascular complications) in all subgroups. Fragility fracture prevalence was low (5.2%) and not different between diabetes groups. Fracture patients had lower BMDs compared with those without fractures; however, BMD T-score was above −2.5 SD in most patients.

Our study shows a similar risk of osteoporosis in patients with type 1 diabetes based on low BMD (T-score < −2.5 SD), which was not different from the prevalence in patients with type 2 diabetes despite them being approximately 20 years older. The FN-BMD was particularly decreased; therefore evaluation of osteoporosis risk in younger patients with type 1 diabetes should include both spinal and FN-BMD-measurements.

We found increased LS-BMD and FN-BMD in patients with type 2 diabetes compared with a non-diabetic, population-based control group. There was a trend for lower BMD in diabetic patients (type 1 and 2) with osteoporotic fractures compared with those without fractures; however, the fracture threshold is higher than in non-diabetic populations. Further longitudinal cohort studies are required, focusing on the risk of fractures and changes in bone metabolism in patients with diabetes.

BMD measurements and the evaluation of BMD-independent risk factors for fractures should be included in the routine management of patients with diabetes mellitus because the prediction of osteoporosis solely by clinical diabetes-specific parameters was not possible. The evidence suggests that osteoporosis, and related fractures, is a clinically significant and commonly underestimated problem in patients with type 1 and type 2 diabetes mellitus.
http://www.medscape.com/viewarticle/825846_1

No comments:

Wandering Skeleton

Wandering Skeleton
Artist: Joel Hoekstra

Osteoporotic Bone

Osteoporotic Bone
Source: www.mayoclinic.com

How Strontium Builds Bones

Strontium is a mineral that tends to accumulate in bone. Studies have shown that oral doses of strontium are a safe and effective way to prevent and reverse osteoporosis. Doses of 680 mg per day appear to be optimal. See my "For More Information About Strontium" links section.

Osteoporosis is caused by changes in bone production. In healthy young bones there is a constant cycle of new bone growth and bone removal. With age, more bone is removed and less new bone is produced. The bones become less dense and thus more fragile.

Scientists believe that strontium works in two ways. It may stimulate the replication of pre-osteoblasts, leading to an increase in osteoblasts (cells that build bone). Strontium also directly inhibits the activity of osteoclasts (cells that break down bone). The result is stronger bones.

When taking strontium, be sure to take 1200 mg calcium, 1000 IU vitamin D3, and 500 mg magnesium daily. It is best to take strontium late at night on an empty stomach. Calcium and strontium may compete with each other for absorption if taken together.